US EditionInnovent’s Sycume to transform thyroid eye disease treatment landscape in China and Asia: GlobalData - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Innovent’s Sycume to transform thyroid eye disease treatment landscape in China and Asia: GlobalData - Express Pharma
Innovent Biologics has recently received approval for Sycume (teprotumumab biosimilar) to treat thyroid eye disease (TED) in China. It is the country’s first insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody approved for TED by the National Medical Products Administration (NMPA). It represents a significant breakthrough and has the potential to transform the standard of care for TED patients in China and Asia, says GlobalData. S…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
